论文部分内容阅读
目的评价紫杉醇脂质体联合卡铂在三阴性乳腺癌新辅助化疗的临床疗效和不良反应。方法确诊的34例三阴性乳腺癌患者采用紫杉醇脂质体+卡铂方案进行新辅助化疗,紫杉醇脂质体135 mg/m2+卡铂(AUC=6),21 d为1个周期,每位患者取前4周期,紫杉醇脂质体给药前未进行任何预处理。结果 34例均可评价疗效,临床完全缓解为26.5%,临床部分缓解为50%,临床有效率为76.5%,其中病理完全缓解为20.6%。主要不良反应为骨髓抑制、肝功能异常及脱发,多为Ⅰ～Ⅱ度,其发生率分别为61.8%、35.3%和32.4%,无明显超敏反应,无治疗相关性死亡。结论紫杉醇脂质体联合卡铂方案在三阴性乳腺癌新辅助化疗中的临床疗效好,毒副反应少,患者耐受性好。
Objective To evaluate the clinical efficacy and adverse reactions of paclitaxel liposome combined with carboplatin in neoadjuvant chemotherapy of triple negative breast cancer. METHODS: Forty-three patients with triple-negative breast cancer were treated with neoadjuvant chemotherapy with paclitaxel liposome + carboplatin, paclitaxel liposome 135 mg / m2 + carboplatin (AUC = 6) for 21 days for 1 cycle, and each patient In the first 4 cycles, paclitaxel liposomes were administered without any pretreatment. Results All the 34 cases could evaluate the curative effect, the complete clinical remission was 26.5%, the partial clinical remission was 50%, the clinical effective rate was 76.5%, and the pathological complete remission was 20.6%. The main adverse reactions were myelosuppression, liver dysfunction and alopecia, mostly grade Ⅰ ~ Ⅱ, the incidence rates were 61.8%, 35.3% and 32.4% respectively. There was no obvious hypersensitivity reaction and no treatment-related death. Conclusion paclitaxel liposomes combined with carboplatin in neoadjuvant chemotherapy of triple negative breast cancer with good clinical efficacy, fewer side effects, patients with good tolerance.